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This experimental and dose-response curve study aimed to carry out the quality control of 
the Chamomilla recutita sample, as well as to estimate the ideal dose, for anti-inflammatory 
effect, of the extract of its capitula, in patients with phlebitis due to peripheral intravenous 
infusion of antineoplastic chemotherapy and to evaluate the toxicity of this extract in human 
beings. The therapeutic efficacy, concerning the anti-inflammatory potential, of different 
doses of Chamomilla recutita extract were analyzed and compared in 25 patients. The time 
of regression of phlebitis was shorter for groups with 2.5% concentration (mean=29.2h, 
standard deviation = 8.98) and 5% concentration (mean = 38.8h, standard deviation = 
17.47). Local toxicity was almost not observed. This research contributes to the innovation 
of the nursing clinical practice, since it suggests an alternative for the treatment of phlebitis 
through the clinical use of phytotherapeutic drugs. (ClinicalTrials.gov Identifier: NCT 
00989599).
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Aplicação clínica da Chamomilla recutita em flebites: estudo de curva 
dose-resposta
Neste estudo, buscou-se realizar o controle de qualidade da amostra de Chamomilla 
recutita, bem como estimar a dose ideal, para efeito anti-inflamatório, do infuso dos seus 
capítulos florais, em pacientes com flebite, decorrente de infusão intravenosa periférica 
de quimioterapia antineoplásica, e avaliar a toxicidade desse infuso em seres humanos. 
Trata-se de estudo experimental, do tipo curva dose-resposta, no qual foi analisada e 
comparada a eficácia terapêutica, quanto ao potencial anti-inflamatório, de diferentes 
doses do infuso da Chamomilla recutita, em 25 pacientes. O tempo de regressão da flebite 
foi menor para os grupos com concentração 2,5% (média=29,2h, desvio padrão=8,98) 
e 5% (média=38,8h, desvio padrão=17,47) e praticamente não se observou toxicidade 
local. Esta pesquisa contribui para a inovação da prática clínica em enfermagem, uma 
vez que sugere alternativa para o tratamento de flebites, por meio da utilização clínica 
de fitoterápicos (ClinicalTrials.gov Identifier: NCT 00989599).
Descritores: Matricaria; Flebite; Relação Dose-Resposta a Droga.
Aplicación clínica de la Chamomilla recutita en flebitis: estudio de la 
curva dosis-respuesta
En este estudio, se buscó realizar el control de calidad de la muestra de Chamomilla 
recutita, así como estimar la dosis ideal, para efecto antiinflamatorio, de la infusión de 
sus inflorescencias, en pacientes con flebitis proveniente de introducción intravenosa 
periférica de quimioterapia antineoplásica y evaluar la toxicidad de esta infusión en los 
seres humanos. Se trata de estudio experimental, del tipo curva dosis-respuesta, en el cual 
fue analizada y comparada la eficacia terapéutica, en cuanto al potencial antiinflamatorio, 
de diferentes dosis de la infusión de la Chamomilla recutita en 25 pacientes. El tiempo 
de regresión de la flebitis fue menor para los grupos con concentración 2,5% (promedio 
= 29,2h, desviación estándar = 8,98) y 5% (promedio = 38,8h, desviación estándar = 
17,47) y prácticamente no se observó toxicidad local. Esta investigación contribuye para 
la innovación de la práctica clínica en enfermería, una vez que sugiere una alternativa 
para el tratamiento de la flebitis por medio de la utilización clínica de fitoterapéuticos. 
(ClinicalTrials.gov Identifier: NCT 00989599)
Descriptores: Matricaria; Flebitis; Relación Dosis-Respuesta A Droga.
Introduction
Phlebitis can be considered a temporary or 
permanent limiting factor for treatment continuity in 
cancer patients, as, after its occurrence, the peripheral 
venous catheter should be immediately removed(1). 
Depending on the extent of the inflammatory process 
established at the venipuncture site, the vascular 
endothelium suffers irreversible injuries, such as 
phlebosclerosis, so that the venous segment cannot be 
used for new intravenous infusion punctures, nor even 
for simple blood collection(2). Thus, phlebitis prevention, 
control of its evolution after its occurrence and reversal 
of its characteristic inflammatory signs are needed, 
mainly in patients whose venous network is already very 
sensitive as a result of antineoplastic chemotherapy.
Conventionally, as a nursing intervention for 
phlebitis treatment, topical lukewarm compresses are 
indicated to reduce the local inflammatory process. 
Depending on the phlebitis intensity, however, applying 
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compresses alone is not enough to improve the 
inflammatory process, leading to the need to for medical 
prescription of systemic anti-inflammatory agents, 
which constitutes an additional factor for the immune 
system commitment of cancer patients. Therefore, it is 
fundamental for Brazilian nursing to start to research, 
within its professional competency area, on alternative 
and more effective phlebitis treatment forms, using 
phytotherapy for example. The Federal Nursing Council 
establishes and recognizes this practice, through COFEN 
Resolution 197/1997(3), as a specialty and/or qualification 
for nursing professionals.
According to the “Guia para a realização de estudos 
de toxicidade pré-clínica de fitoterápicos”(4) [Guide for 
preclinical phytotherapeutic drug toxicity studies], any 
and all phytotherapeutic or vegetal drugs under analysis 
should obligatorily be submitted to toxicological tests. 
Toxicity studies need to be conducted with standardized 
samples of the phytotherapeutic or vegetal drug based 
on which it is produced. According to the same standard, 
toxicity should be assessed after the user’s exposure to a 
single or fractionated dose, which should be administered 
to the patient within 24 hours.
The Lista de Registro Simplificado [Simplified 
Registry] by the Brazilian Health Surveillance Agency(5) 
already contains Chamomilla recutita (L.) Rauschert 
(Asteraceae), so that proving efficacy and safety is not 
needed. Infusion is not considered a pharmaceutical form 
yet in Brazil, however – as opposed to what happens in 
other countries like Germany, which considers C. recutita 
infusion a pharmaceutical form. This research aimed to 
estimate the ideal dose, for anti-inflammatory purposes, 
of C. Recutita floral capitula infusion, in patients with 
phlebitis due to peripheral intravenous infusion of 
antineoplastic chemotherapy, as well as to assess the 
toxicity of this infusion in human beings. Besides, the 
vegetal species used was especially grown, standardized 
and characterized with a view to certification for medicinal 
use and later validation of its therapeutic efficacy and 
safety, as a secondary study goal.
Method
Cultivation, standardization and characterization of 
C. recutita
“Cultivar Mandirituba” C. recutita seeds were used 
for planting, donated by Empresa de Assistência Técnica 
e Extensão Rural do Paraná (EMATER-PR) [Paraná State 
Rural Technical Assistance and Service Company]. 
Organic planting was followed, in an aviary bed, located 
in a nursery in the Medicinal Plant Garden of the Federal 
University of Mato Grosso do Sul (HPM-UFMS). Sowing 
occurred in May 2005. During the cultivation cycle, weed 
control, performed with the help of a hoe, and irrigations 
through sprinklers were done whenever necessary. No 
pesticides were used directly on the plants to control 
plagues or diseases. Manual harvesting occurred in 
September 2005 by technicians from HPM-UFMS. The 
drying of the collected floral capitula was done in a 
forced-air circulation glasshouse with temperature 
ranging between 36º ± 2ºC, to constant mass, resulting 
in 56.57 million ha-1, equivalent to 8kg of floral capitula of 
C. recutita. After drying, the floral capitula of C. recutita 
were stored in lidded glass pots and kept refrigerated.
The physical-chemical evaluation of C. recutita 
inflorescences was done in accordance with the methods 
described in Farmacopéia Brasileira(6) and USP 28(7). A 
sample of about 500.0 g was grinded and submitted 
to physical-chemical characterization, including 
identification, purity and integrity tests and marker 
dosage. This dosage consisted in the quantification of 
total flavonoids in the floral capitula and α-bisabolol in 
essential oil.
After being submitted to the describe cultivation, 
harvesting, drying and storage processes, the dry floral 
capitula of C. recutita were destined for laboratory 
analysis, when the excellent quality of the raw material 
was verified, as evidenced in the physical-chemical 
characterization of the sample (Table 1).
Table 1 – Physical-chemical characterization of C. Recutita inflorescences
Test Result References
Aspect Dehydrated, slightly erased inflorescences. Presence of little powder. USP 28(7)
Organoleptic characteristics Aromatic, pleasant, sweet scent. Bitter taste. USP 28(7)
Humidity content 13.0% m/m Farm. Bras.(6)
Total Ashes 7.4% m/m Farm. Bras.(6)
Ashes insoluble in HCl 1.1% m/m Farm. Bras.(6)
(continue...)
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Test Result References
Strange material 4.8% m/m Farm. Bras.(6)
Total flavonoid content 2.5% m/m Dowd(8); Jay(9)
Essential oil content 0.4% v/m, bluish-colored oil Farm. Bras.(6)
70% ethanol-extractable material 16.9% m/m Farm. Bras.(6)
Table 1 – (continuation)
Total flavonoid content in the floral capitula 
of chamomile was determined by 425 nm 
spectrophotometry, according to an adapted method 
described in literature(8-9). Total flavonoid concentration 
(expressed in quercetin) was calculated per 100.0 
g of the sample. The same procedure was applied to 
determine total flavonoid contents in the four infusion 
dosages (Table 1), with a view to better characterization 
and comparison with future study data.
α-bisabolol content was determined by gas 
chromatography with flame ionization detector (GC-FID). 
Therefore, the essential C. recutita oil was previously 
extracted, using hydrodistillation with a Clevenger 
apparatus. Triple analysis was performed, using an 
analytic α-bisabolol curve ranging from 200.0 to 1000.0 
µg/mL, using piperonal as internal standard.
Finally, the main constituent elements present in the 
essential oil were identified, using gas chromatography 
with mass detector (GC-MD).
α-bisabolol content in the essential oil could 
be quantified through the equation of the straight 
line obtained from the analytic curve with internal 
standardization (R = 0.9993), corresponding to 10.9% 
m/m. According to GC-MD analysis of the essential oil, 
five major peaks of the plant’s main active principles 
could be clearly identified, which should be highlighted: 
α-bisabolol oxide B (19.6%); α-bisabolone oxide (5.2%); 
α-bisabolol (9.0%); camazulene (1,3%); α-bisabolol 
oxide A (40.7%), besides spathulenol, β-elemene, 
limonene oxide, β-farnesene and d-nerolidol.
Clinical Phase
A dose response curve trial was carried out, in which 
the therapeutic efficacy of different C. recutita infusion 
doses was analyzed and compared in cancer patients 
with phlebitis deriving from peripheral intravenous 
infusion of antineoplastic chemotherapy, looking at 
the anti-inflammatory potential. Dose response curve 
studies demonstrate the relation between the dose 
(concentration) of an administered drug and the produced 
tissue response or effect, permitting knowledge on the 
adequate dose based on the wanted and unwanted 
effects obtained during the clinical application(10).
The research was carried out at a public hospital in 
the Federal District, which is a tertiary referral institution 
for cancer care and offers 18 hematology and clinical 
oncology beds. The sample comprised 25 patients who 
formally agreed to participate by signing the Informed 
Consent Term (ICT). All patients had been diagnosed with 
degree-2 phlebitis according to the staging proposed by 
the Infusion Nursing Society(11) and were between 20 
and 30 years old. Thirteen participants were women and 
12 men, whose white blood cell count showed adequate 
normality levels for neutrophil (2000 – 7500/µl) and 
monocyte (100 - 800/µl)(12) counts, medically diagnosed 
with Acute Myeloid Leukemia (AML), submitted to the 
first, second or third cycle of the chemotherapy protocol 
IDA + ARA-C (idarubicin and cytarabine), through 
peripheral intravenous infusion.
The exclusion criteria were the patients’ affirmative 
response when asked about previous adverse reactions to 
chamomile or any plant in the Asteraceae or Compositae 
family, medical prescription of systemic or topical anti-
inflammatory drug on the phlebitis site and refusal to 
continue participating in the study.
The primary researcher established the criterion 
to allocate the subjects to the groups as follows: the 
first selected patient was automatically allocated to trial 
group A, the second to group B, the third to group C, 
the fourth to group D and the fifth to the control group. 
This process was repeated until 25 patients had been 
allocated.
Data were collected between September and 
December 2005. Patients who complied with the 
selection criteria were allocated in five groups, one of 
which was the control group. A 20 cm2 cotton compress 
was used for the intervention, moistened with the C. 
recutita infusion when applied in the trial groups (Table 
1) or with lukewarm water in the control group. In all 
groups, temperature was set at 38 °C.
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The graphs showing the dose-response curve are 
semi-logarithmic(10), with the dose axis showing the 
drug concentration in exponential progress. Hence, in 
this study, the researchers took care to establish the 
following dose concentrations, specified in Table 1.
Table 2– Distribution of patient groups according to infusion dose
Group Portion (g) of dehydrated floral capitula of C. recutita in 400 mL of water Dose (%) Total flavonoid content (mg/mL)
A 5 1.25% 0.02
B 10 2.5% 0.04
C 20 5.0% 0.08
D 40 10.0% 0.19
After removing the peripheral venous device, 
the moistened compress was applied on the phlebitis 
evidenced in the subject’s upper limb, three times per 
day (morning, afternoon and night), according to the 
dose established in the group the patient had been 
allocated to, i.e. trial group A, B, C, D or control. As 
soon as the compress had been applied, the limb was 
wrapped in transparent PVC film to preserve local heat. 
Compress application time was set at 20 minutes for all 
groups and compresses were changed every 5 minutes. 
Only the main researcher applied the intervention in 
all patient groups. After the phlebitis diagnosis, the 
application time of the first compress was registered. 
The treatment site was assessed daily at three distinct 
times: at 8, 13 and 19 hours, with a view to uniform 
readings. The intervention was continued until the 
complete disappearance of the erythema, considered 
the main outcome.
The erythema was chosen as the parameter to 
assess the inflammatory regression as this is a classical 
sign of any inflammation and an objective data, 
present in degree-2 phlebitis (local pain, erythema 
and/or edema), according to the staging proposed by 
the Infusion Nursing Society(11). Thus, the erythema 
regression time constituted a safe parameter to monitor 
the inflammation, offering the advantage that nursing 
professionals know and identify clinical phlebitis 
staging criteria very well, entailing additional security 
for assessment precision. To measure to erythema, 
transparent paper ruled in one-centimeter squares was 
used, based on which the erythema area was calculated 
very precisely, so that any alteration in the dependent 
variable could be identified.
Like the subject allocation procedure to the 
respective groups, the same researcher performed the 
intervention and evaluation.
Toxicity was investigated through visual assessment 
of the application site, looking for any signal that would 
indicate any reaction to the infusion, and also for 
symptoms. For toxicological evaluation, a compress was 
applied with the dose that presented the best dose-
response effect in four other subjects with the same 
characteristics as the subjects but who did not present 
phlebitis, in compliance with  (ANVISA) [National 
Health Surveillance Agency] Resolution RE Number 90, 
issued on March 16th 2004 – about toxicity evaluation 
of phytotherapeutic interventions – which suggests 
additional toxicity evaluation in healthy individuals(3).
One-way variance analysis (ANOVA) was used for 
statistical analysis of the results, followed by multiple 
comparison test – Bonferroni test(13-14), using Graph 
Pad Prism* software, demo version, 5.0 for Windows. 
Significance was set at 5% in all tests. Approval for this 
research project was obtained from the Institutional 
Review Board of the Federal District Health Secretary, 
opinion number 062/2004.
Results
Intergroup comparison showed a statistically 
significant difference in the groups that received 2.5% 
and 5% infusions (i.e. corresponding to total flavonoid 
contents of 0.04 and 0.08 mg/mL, respectively) 
regarding the phlebitis regression time in comparison 
with the other groups (concentrations of 1.25% and 
10%) and the control group (Figure 1)
Erythema regression time in the study sample 
ranged between 19 and 120 hours for different dose 
concentrations used. The group in which the 2.5% 
concentration compress was used showed the shortest 
regression times: 19 and 24 hours (Table 3). The dose-
response curve (Figure 2) evidences that the average 
phlebitis regression time was shorter for the 2.5% 
concentration group (mean = 29.2h, standard deviation 
* Available from: http://www.graphpad.com/demos.
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= 8.98), followed by the 5% concentration group (mean 
= 38.8h, standard deviation = 17.47), and longer for 
the 1.25% (mean = 57.8h, standard deviation = 11.10) 
and 10% concentration groups (mean = 49.4h, standard 
deviation = 4.67). Mean regression time in the control 
group was 110.4h and standard deviation 13.15.
Figure 1 – Effect of different C. recutita infusion 
concentration on the reduction of phlebitis in patients 






















Legend: a = p<0.001 related to control; p<0.01 related to 1.25%; p<0.05 
related to 10%; p>0.05 related to 5%, b = p<0.001 related to control; 
p>0.05 related to 10%, c = p<0.001 related to control; p>0.05 related 
to 10%. Statistical analysis using ANOVA followed by Bonferroni multiple 
comparison test.
Table 3 – Regression time, in hours, of phlebitis according 
to infusion dose group of C. recutita floral capitula
Dose (%) Regression Time (hours)
0 96 96 120 120 120
1.25 48 48 54 67 72
2.5 19 24 30 30 43
5 30 30 43 43 48
10 43 48 48 48 54
Figure 2 – Dose-response curve according to mean 
regression times, in hours and infusion concentrations 
of 1.25%, 2.5%, 5% and 10%, respectively, of C. 































As for toxicity, moderate to severe itching was 
reported on the left forearm of one of the patients 
allocated in trial group C, whose compress had been 
applied on the anterior front forearm. As the itching 
expanded, the transparent PVC film used on the entire 
forearm could have caused this. The subject was 
forwarded to the medical team, medicated with an anti-
histaminic drug and showed complete regression of the 
itching within two hours. Local treatment was continued 
with warm water compresses at 38° C until the complete 
regression of the erythema.
With regard to toxicity evaluation in subjects without 
phlebitis (n=4), no manifestations of hypersensitivity 
reactions occurred, nor reports of burning, itching or any 
other symptoms related with possible hypersensitivity to 
the drug.
Discussion
It is fundamental to determine the total flavonoid 
contents when assessing a plant’s quality, especially in 
studies that use flavonoids for therapeutic purposes(15). 
Tests involving about 100 samples of 12 chamomile 
varieties cultivate in identical conditions showed flavonoid 
contents ranging between 1.0 and 2.6%, while twenty 
other samples of different origins showed total flavonoid 
content levels varying between 0.3 and 3.0%(15). The 
sample used in this study showed 2.5% m/m of total 
flavonoids, in line with previously found results. As for 
α-bisabolol content in essential oil, the level identified 
in the sample (10.9% m/m) surpassed literature 
recommendations according to the used temperature, 
which is 7%(15). Qualitative analysis of the plant’s active 
principles confirmed available literature data about the 
chemical composition of C. recutita, describing terpenes 
(α-bisabolol, bisabolol oxide A and B, camazulene and 
sesquiterpenes), flavonoids (apigenin-7-glucoside, 
luteolin, quercetin), coumarins (umbelliferone) and 
steroids(16). It should be reminded that these elements, 
terpenes, steroids and sesquiterpenes exert anti-
inflammatory effects, generally inhibiting the classical 
route of the complement system, interfering, in turn, in 
arachidonic acid metabolism(17).
With regard to the clinical phase, research subjects 
in all groups were comparable, as the main confounding 
factors, including age, sex, white blood cell count and 
baseline disease were similar. Among the 25 participants, 
those in group A (dose 1.25%) showed the longest 
inflammation process regression time (range: 48 – 
72h), while those in groups B and C showed the shortest 
regression time (range: 19 – 48h). Group D showed a 
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longer regression time than groups B and C because, 
despite a higher dose – 40 g of floral capitula of C. 
recutita – the compress could not be totally moistened 
with the quantity of solvent used. This quantity did not 
need to be adjusted though, as lower doses had already 
demonstrated an excellent effect in terms of regression 
time of the inflammatory process.
Other clinical trials have confirmed the anti-
inflammatory effect of C. recutita in radiation dermatitis, 
through the use of ointments with chamomile extract 
(Kamilosan®)(18), in mucositis, through oral solution 
(Kamilosan® Solução Oral)(19), in contact dermatitis 
and eczema, through ethanolic extract(20-21), showing 
even superior efficacy results when compared with 
steroidal and non-steroidal anti-inflammatory drugs(21). 
Researchers(22) have assessed the efficacy of medical 
plant infusions (chamomile, salvia and calendula) 
for topical application in the treatment of Hand-Foot 
Syndrome resulting from intravenous capecitabine 
infusion, an antineoplastic chemotherapy drug used 
in breast cancer patients. The sample comprised 11 
patients who immersed their hands and feet into the 
infusion daily. Significant regression of the inflammatory 
process was found in all cases.
As for the dose, literature recommends 
concentrations between 3 and 10% for external use 
in compresses(23-24). It was observed, however, that 
with 2.5% concentrations, results were as satisfactory 
as with 5% concentrations, to the extent that the 
shorted regression time of the inflammation process 
was obtained in two patients, i.e. 19 and 24 hours. 
Both concentrations showed statistically significant 
results when compared mutually (p<0.05) and with 
the control group (p<0.001). When compared with the 
other concentrations (1.25% and 10%), the 2.5% dose 
showed a statistically significant difference (p<0.05), 
while the 5% dose showed no statistically significant 
difference with the other doses.
Therefore, the researchers decided to choose the 
2.5% concentration (10 g/400 mL) for floral capitula 
infusions of as the standard dose for this study, although 
literature recommends using concentrations between 3 
and 10% for compresses. This small difference of -0.5% 
between the result obtained in the dose-response curve 
and the concentration recommended in literature (at 
least 3%) can be attributed to the excellent quality of 
the test sample, of Brazilian origins. Besides, it should be 
highlighted that literature itself shows different variations 
in terms of quantity definitions and even measurement 
units. The US Pharmacopeia, for example, indicates the 
use of two dessert spoons for external use, equivalent 
to approximately 6g of dry floral capitula of C. recutita 
in 250 mL of water(25), i.e. 2.4%, which is basically the 
same standard dose found in this research phase. The 
same source highlights that concentrations between 3 
and 10% are indicated for ointments and gels.
It is also important to highlight that using less grams 
of floral capitula with better results in terms of time 
for phlebitis regression generates a better cost-benefit 
relation and, hence, greater advantage for consumers, 
due to the obvious economy of the main resource.
Itching was reported in one of the patients allocated 
in trial group C, with a 5% infusion concentration. The 
reported hypersensitivity reaction – itching – occurred 
across the subject’s left forearm, who classified it as 
moderate to intense when the researcher asked about the 
intensity, although the compress had only been applied 
on the anterior front middle third of the left forearm. 
With regard to this episode, although allergic reactions 
to C. recutita are quite rare, these can happen, to the 
extent that one of the exclusion criteria was exactly 
the patient’s affirmative response as to any adverse 
reaction to chamomile or any plant from the Asteraceae 
or Compositae family.
It should be clarified that the sites where the 
compresses were applied, in the trial as well as in the 
toxicity control group, were assessed for an additional 
two days after the application, with a view to investigating 
late signs and symptoms of toxicity. This was not verified 
in any of the other subjects who accepted to participate 
in the research. As for the itching in one of the sample 
subjects, the symptom regressed within 72 hours, 
without the need for any medication intervention.
Conclusion
The standardization of vegetal raw material, ranging 
from the selection of the species, seeding, cultivation, 
harvesting, drying, storage and quality assessment 
is fundamental, mainly when used for therapeutic 
purposes, like in the case of this research.
Based on the results, it can be inferred that, at 
α = 5%, the C. recutita infusion presents minimal or 
almost zero toxicity for topical application. This study 
also demonstrated that the 2.5% concentration for floral 
capitula infusion of C. recutita, when applied for anti-
inflammatory purposes in case of phlebitis deriving from 
peripheral intravenous chemotherapy infusion, is as 
effective as the concentration suggested by literature, 
i.e. between 3 and 10%.
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This research contributes to the innovation of clinical 
nursing practice, as it suggests a treatment alternative 
for phlebitis deriving from peripheral intravenous 
infusion during antineoplastic chemotherapy. Moreover, 
theoretical support is provided regarding the methods to 
adopt for the clinical use of phytotherapeutic drugs.
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